Suven Life Sciences Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Suven Life Sciences Ltd trades at ₹326, in a confirmed uptrend and 10 weeks into that stage. That is +50.7% against its own 200-day average. It sits at 86% of a 52-week range of ₹130 to ₹358. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 20 straight weeks.

Today the stock is in a confirmed uptrend — week 10 of stage 2, confirmed. At ₹326 it trades +50.7% versus its 200-day average and sits at 86% of its 52-week range (₹130–₹358).

Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +2,446% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 20 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 16th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Suven Life Sciences Ltd trades at 2.6× P/E, near the bottom of its own range — cheaper only 16% of the time. Its long-run median P/E is 3.2×, measured across 3.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 2.6× is near the bottom of its own range — cheaper only 16% of the time, against a long-run median of 3.2× measured over 3.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

The price move, decomposed: over 3y, of the +74.6%/yr price move, ~+23.4%/yr came from earnings growth and ~+51.2 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Suven Life Sciences Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

43.1/100 — rank 28 of 43 in Pharma - Formulators · 57% evidence confidence

Suven Life Sciences Ltd scores 43.1 out of 100 against the 43 companies it is compared with in Pharma - Formulators, ranking 28. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 18.1 + 6.9 + 10 + 8.1 = 43.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Suven Life Sciences Ltd reported ₹2.0 Cr of revenue in the Mar 26 quarter, +100.0% year on year. That is the 2nd straight quarter of year-on-year growth. Over 10 years it has compounded at −34.7% a year. The last full year, FY26, came in at ₹7.0 Cr. The last four reported quarters add to ₹8.0 Cr.

Suven Life Sciences Ltd reported ₹2.0 Cr of revenue in the Mar 26 quarter, +100.0% year on year. That is the 2nd straight quarter of year-on-year growth. Over 10 years it has compounded at −34.7% a year. The last full year, FY26, came in at ₹7.0 Cr. The last four reported quarters add to ₹8.0 Cr.

FY26 revenue came in at ₹7.0 Cr (+0.0% on the year), capping 10 years at −34.7% compound. The latest quarter (Mar 26) printed ₹2.0 Cr, +100.0% year on year — the 2nd consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +45.8% growth against the decade's −34.7% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +14.3% over the last 4 quarters against −14.7%/yr over the last 8 — accelerating.

→ Revenue grew — did margins hold as it scaled? Next: −3,331.0% this quarter (−350.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Suven Life Sciences Ltd's operating margin is −3,331.0% in the Mar 26 quarter, −350.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −4,001.0% to 32.0%. The current quarter sits inside that band.

Suven Life Sciences Ltd's operating margin is −3,331.0% in the Mar 26 quarter, −350.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −4,001.0% to 32.0%. The current quarter sits inside that band.

The latest quarter's operating margin is −3,331.0%, −350.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −4,001.0%–32.0%.

🚨 Why the margin moved: operating margin went −350.0 pp year on year while gross margin went +0.0 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

→ Margins slipped — did that reach the bottom line? Next: profit null in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Suven Life Sciences Ltd posted a net loss of ₹46.0 Cr in the Mar 26 quarter. That quarter carries a one-off item larger than its own revenue, so the year-on-year figure is an artefact rather than a trading result. The full FY26 year was a loss of ₹276 Cr. That loss is 2,300.0% of the quarter's revenue.

Suven Life Sciences Ltd posted a net loss of ₹46.0 Cr in the Mar 26 quarter. That quarter carries a one-off item larger than its own revenue, so the year-on-year figure is an artefact rather than a trading result. The full FY26 year was a loss of ₹276 Cr. That loss is 2,300.0% of the quarter's revenue.

Mar 26 profit was ₹−46.0 Cr, null year on year. On the full year, FY26 printed ₹−276 Cr (null).

🚨 Read this profit with care: at ₹−46.0 Cr it is larger than the whole quarter's revenue of ₹2.0 Cr — no operating business earns more than it sells, so this is a one-off item (a debt-to-equity conversion, a tax write-back or an asset sale), not money the business earned. The underlying operations are running at −3,331.0% operating margin; the year-on-year jump and any P/E built on this number are artefacts of the one-off, not a real earnings turn.

→ Profit rose — but did the cash follow? Next: 87% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 87% of Suven Life Sciences Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹−302 Cr of operating cash against ₹−276 Cr of profit. After ₹23.0 Cr of capital spending, ₹−325 Cr was left as free cash.

FY26: operating cash of ₹−302 Cr against reported profit of ₹−276 Cr, leaving free cash of ₹−325 Cr after ₹23.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 87% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 87%: the cash cycle stretched 30 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 3.2× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹58.0 Cr of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Suven Life Sciences Ltd's cash conversion cycle runs 78 days in FY26, up from 48 days in FY21. Capital spending ran ₹58.0 Cr over the last 3 years. At FY26 sales of ₹7.0 Cr each day of that cycle holds about ₹0.0 Cr, so roughly ₹1.0 Cr sits inside the business at any moment.

FY26: debtors at 78 days (an asset-light business — no inventory to speak of) — for a full cycle of 78 days, looser than FY21's 48.

In money terms: at FY26 sales of ₹7.0 Cr, each day of the cycle holds about ₹0.0 Cr — so the 78-day loop keeps roughly ₹1.0 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹58.0 Cr over the last 3 fiscal years against ₹18.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹4.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is −77% and the ROIC − WACC spread is −539.2 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Suven Life Sciences Ltd earns a ROCE of −77% in FY26. That is up from a trough of −118% in FY22. Return on invested capital clears the cost of that capital by −539.2 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −3,942.9% net margin on 0.01× asset turns.

FY26 ROCE is −77%, recovered from a FY22 trough of −118% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): −3,942.9% net margin × 0.01× asset turns × 1.06× balance-sheet leverage ≈ −41.8% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: −527.2% − 12.0% = a −539.2 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.03.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Suven Life Sciences Ltd carries total debt of ₹17.0 Cr against shareholder equity of ₹591 Cr as of Mar 26, a debt-to-equity of 0.03 — effectively unlevered. On the annual view that ratio went from 0.03 in FY22 to 0.03 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹17.0 Cr against shareholder equity of ₹591 Cr — a debt-to-equity of 0.03. On the annual view, debt-to-equity went from 0.03 (FY22) to 0.03 (FY26). The returns on this page are earned, not borrowed.

→ Who owns this, and are they adding or leaving? Next: Promoters cut 4.8 points over 8 quarters.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters cut 4.8 points of Suven Life Sciences Ltd over 8 quarters, the biggest move on the register. That takes promoters to 65.5% of the company. Domestic institutions moved +1.7 points over the same window, to 2.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: −4.8 points over 8 quarters to 65.5%; Domestic institutions: +1.7 points over 8 quarters to 2.7%; Foreign institutions: +0.1 points over 8 quarters to 0.5%.

🚨 Why the register moved: promoters drove it (−4.8 points), absorbed on the other side by domestic institutions (+1.7 points) — distribution into the market’s bid.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Suven Life Sciences Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions